BriaCell Reports Prolonged Survival in Phase 2 Metastatic Breast Cancer Trial

BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an announcement.

BriaCell Therapeutics reported updated Phase 2 data for its Bria-IMT immunotherapy regimen in metastatic breast cancer, showing that 9 of 25 patients treated since 2022 remain alive more than 18 to 47 months after enrollment, markedly exceeding survival benchmarks reported for standard-of-care therapies in comparable late-stage populations. The company highlighted detailed cases of heavily pretreated women, including patients previously exposed to antibody-drug conjugates such as Enhertu and Trodelvy, who achieved prolonged survival and, in some instances, significant disease control without Bria-IMT–related treatment discontinuations. Comparative analyses suggest that Bria-IMT plus checkpoint inhibitor therapy may deliver higher one- and two-year survival rates than several referenced regimens, supporting BriaCell’s view that its approach could address a substantial unmet need in metastatic breast cancer and reinforcing the strategic importance of its ongoing pivotal Phase 3 trial, which is designed to confirm overall survival benefits and potentially reposition the company within the competitive oncology landscape.

The most recent analyst rating on (TSE:BCT) stock is a Hold with a C$6.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

The score is held down primarily by weak financial performance (no revenue, widening losses, and significant cash burn with likely ongoing financing needs). Technicals are mixed with some shorter-term strength but negative MACD and a price still far below the 200-day average. Valuation contributes limited support due to a negative P/E and no dividend yield.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, with a current emphasis on treatments for metastatic breast cancer. Its lead candidate, the Bria-IMT regimen, is designed to improve survival outcomes in heavily pretreated patients and has been granted Fast Track Designation by the U.S. Food and Drug Administration, underscoring its potential in a high-need oncology market.

Average Trading Volume: 16,398

Technical Sentiment Signal: Sell

Current Market Cap: C$39.63M

For a thorough assessment of BCT stock, go to TipRanks’ Stock Analysis page.